• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's After-Market Session

    4/12/22 5:51:33 PM ET
    $AGRX
    $ALZN
    $ANIX
    $BLI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AGRX alert in real time by email

    Gainers

    • Alzamend Neuro (NASDAQ:ALZN) shares rose 19.6% to $1.22 during Tuesday's after-market session. Today's trading volume for this security ended up closing at 223.2K shares, which is 17.9 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $109.9 million.
    • Agile Therapeutics (NASDAQ:AGRX) shares increased by 18.74% to $0.22. At the close, Agile Therapeutics's trading volume reached 6.5 million shares. This is 341.7% of its average volume over the last 100 days. The company's market cap stands at $30.0 million.
    • Biophytis (NASDAQ:BPTS) shares moved upwards by 15.55% to $2.08. The market value of their outstanding shares is at $30.6 million.
    • Anixa Biosciences (NASDAQ:ANIX) stock increased by 9.66% to $2.86. The market value of their outstanding shares is at $86.3 million.
    • Kaleido Biosciences (NASDAQ:KLDO) shares rose 9.36% to $0.19. This security traded at a volume of 878.0K shares come close, making up 140.4% of its average volume over the last 100 days. The company's market cap stands at $8.0 million.
    • Regulus Therapeutics (NASDAQ:RGLS) shares moved upwards by 7.04% to $0.26. The market value of their outstanding shares is at $37.9 million.

    Losers

    • NanoString Technologies (NASDAQ:NSTG) stock decreased by 30.1% to $23.05 during Tuesday's after-market session. This security traded at a volume of 120.5K shares come close, making up 23.1% of its average volume over the last 100 days. The company's market cap stands at $1.0 billion.
    • Liquidia (NASDAQ:LQDA) stock fell 11.96% to $5.45. Trading volume for this security closed at 70.0K, accounting for 14.4% of its average full-day volume over the last 100 days. The company's market cap stands at $285.7 million.
    • Histogen (NASDAQ:HSTO) stock decreased by 11.32% to $0.37. Histogen's trading volume hit 6.5 million shares by close, accounting for 635.4% of its average volume over the last 100 days. The company's market cap stands at $18.4 million.
    • Berkeley Lights (NASDAQ:BLI) shares declined by 8.98% to $5.55. The company's market cap stands at $375.6 million.
    • Trevena (NASDAQ:TRVN) shares decreased by 5.76% to $0.39. The market value of their outstanding shares is at $64.4 million.
    • Icosavax (NASDAQ:ICVX) shares decreased by 5.69% to $8.3. The company's market cap stands at $329.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AGRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGRX
    $ALZN
    $ANIX
    $BLI

    CompanyDatePrice TargetRatingAnalyst
    Liquidia Corporation
    $LQDA
    10/20/2025$31.00Overweight
    Wells Fargo
    Liquidia Corporation
    $LQDA
    8/15/2025$43.00Buy
    Jefferies
    Liquidia Corporation
    $LQDA
    5/19/2025$13.00Perform → Underperform
    Oppenheimer
    Regulus Therapeutics Inc.
    $RGLS
    3/27/2025$3.00 → $6.00Equal Weight → Overweight
    Wells Fargo
    Anixa Biosciences Inc.
    $ANIX
    3/21/2025$10.00Buy
    Maxim Group
    Liquidia Corporation
    $LQDA
    12/20/2024$20.00Overweight
    Wells Fargo
    Liquidia Corporation
    $LQDA
    10/16/2024Sector Outperform
    Scotiabank
    Liquidia Corporation
    $LQDA
    8/19/2024Outperform → Strong Buy
    Raymond James
    More analyst ratings

    $AGRX
    $ALZN
    $ANIX
    $BLI
    SEC Filings

    View All

    SEC Form 144 filed by Liquidia Corporation

    144 - Liquidia Corp (0001819576) (Subject)

    3/27/26 4:27:07 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Liquidia Corporation

    144 - Liquidia Corp (0001819576) (Subject)

    3/26/26 4:21:19 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alzamend Neuro Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

    8-K - Alzamend Neuro, Inc. (0001677077) (Filer)

    3/20/26 4:30:20 PM ET
    $ALZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGRX
    $ALZN
    $ANIX
    $BLI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Tentative Approval for YUTREPIA issued to Liquidia Technologies, Inc.

    Submission status for Liquidia Technologies, Inc.'s drug YUTREPIA (ORIG-1) with active ingredient TREPROSTINIL has changed to 'Tentative Approval' on 11/04/2021. Application Category: NDA, Application Number: 213005, Application Classification: Type 3 - New Dosage Form

    11/18/21 2:49:33 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    September 7, 2021 - Coronavirus (COVID-19) Update: September 7, 2021

    For Immediate Release: September 07, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: As part of the FDA’s effort to protect consumers, the agency issued a warning letter to Kaleido Biosciences, Inc. for not complying with federal laws and regulations, including laws and regulations to protect individuals participatin

    9/7/21 4:11:11 PM ET
    $KLDO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGRX
    $ALZN
    $ANIX
    $BLI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Bloch Stephen M

    4 - Liquidia Corp (0001819576) (Issuer)

    3/30/26 5:43:08 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Moomaw Scott

    4 - Liquidia Corp (0001819576) (Issuer)

    3/25/26 4:30:15 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Saggar Rajeev sold $1,283,834 worth of shares (35,365 units at $36.30), decreasing direct ownership by 17% to 174,473 units (SEC Form 4)

    4 - Liquidia Corp (0001819576) (Issuer)

    3/17/26 4:31:24 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGRX
    $ALZN
    $ANIX
    $BLI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Baskies Arnold M bought $30,400 worth of shares (10,000 units at $3.04), increasing direct ownership by 8% to 135,000 units (SEC Form 4)

    4 - Anixa Biosciences Inc (0000715446) (Issuer)

    1/29/26 8:58:38 AM ET
    $ANIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Titterton Lewis H Jr bought $30,800 worth of shares (10,000 units at $3.08), increasing direct ownership by 1% to 953,334 units (SEC Form 4)

    4 - Anixa Biosciences Inc (0000715446) (Issuer)

    8/4/25 9:00:05 AM ET
    $ANIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Kumar Amit bought $15,800 worth of shares (5,000 units at $3.16), increasing direct ownership by 0.87% to 579,925 units (SEC Form 4)

    4 - Anixa Biosciences Inc (0000715446) (Issuer)

    7/31/25 9:00:04 AM ET
    $ANIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGRX
    $ALZN
    $ANIX
    $BLI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing

    Phase 1 study met primary endpoints, showed safety and tolerability at the maximum tolerated dose, and generated protocol-defined immune responses in 74% of participantsSAN JOSE, Calif., April 1, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has entered into a development and manufacturing agreement with Cytovance Biologics (www.cytovance.com), a leading full-service contract development and manufacturing organization ("CDMO") specializing in mammalian and microbially expressed biologics, to produce cGMP clinical materials for its planned Phase 2 clinica

    4/1/26 8:50:00 AM ET
    $ANIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer

    Dr. Robert Wenham of Moffitt Cancer Center and principal investigator of the trial to present lira-cel trial statusSAN JOSE, Calif., March 30, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Robert Wenham, Chair of the Gynecologic Oncology Department at Moffitt Cancer Center and principal investigator for the Company's ongoing ovarian cancer CAR-T therapy Phase 1 trial, will be presenting at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer, being held April 10 – 13, 2026, in San Juan, Puerto Rico.

    3/30/26 9:05:00 AM ET
    $ANIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions

    Bioequivalence Confirmed: AL001 delivered 101% of total lithium blood exposure and 97% of peak lithium levels vs. standard lithium carbonateSuperior Brain Penetration: AL001 showed numerically higher lithium concentrations in all measured brain regions, including whole brainFaster Brain Uptake: AL001 reached peak brain concentration in 6.7 hours vs. 8.4 hours for standard lithium carbonateATLANTA, March 26, 2026 /PRNewswire/ -- Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder type 1 ("BD"), major depressive disorder ("MDD") and post-trauma

    3/26/26 8:00:00 AM ET
    $ALZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGRX
    $ALZN
    $ANIX
    $BLI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on Liquidia Technologies with a new price target

    Wells Fargo initiated coverage of Liquidia Technologies with a rating of Overweight and set a new price target of $31.00

    10/20/25 8:01:49 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies resumed coverage on Liquidia Technologies with a new price target

    Jefferies resumed coverage of Liquidia Technologies with a rating of Buy and set a new price target of $43.00

    8/15/25 7:59:34 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Liquidia Technologies downgraded by Oppenheimer with a new price target

    Oppenheimer downgraded Liquidia Technologies from Perform to Underperform and set a new price target of $13.00

    5/19/25 8:49:50 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGRX
    $ALZN
    $ANIX
    $BLI
    Leadership Updates

    Live Leadership Updates

    View All

    Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors

    BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Arthur S. Kirsch to the Company's Board of Directors, effective immediately. Mr. Kirsch has decades of experience in investment banking and capital markets, as well as extensive knowledge of the healthcare and life sciences industries. Mr. Kirsch is currently a Senior Advisor with Alvarez & Marsal's Life Sciences Industry Group, and over the course of his 30-year career has held numerous roles in mergers and acqui

    2/24/25 7:00:00 AM ET
    $AVIR
    $LQDA
    $KDMN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Pharmaceuticals

    Anixa Biosciences Appoints Suyasha Gupta as Senior Director of Clinical Development

    SAN JOSE, Calif., Oct. 7, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced the appointment of Suyasha Gupta as Senior Director of Clinical Development. In this role, Ms. Gupta will work closely with Dr. Pamela Garzone, Chief Development Officer, to oversee the Company's ongoing Phase 1 breast cancer vaccine and Phase 1 ovarian cancer CAR-T therapy clinical trials, as well as the upcoming Phase 2 breast cancer vaccine clinical trial. Suyasha Gupta is

    10/7/24 8:30:00 AM ET
    $ANIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

    Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), as an independent member of its Board of Directors. Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum's board. Ms. Boyce has extensive expertise in global pharmaceut

    6/24/24 4:05:00 PM ET
    $CTNM
    $IONS
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Pharmaceuticals
    Medicinal Chemicals and Botanical Products

    $AGRX
    $ALZN
    $ANIX
    $BLI
    Financials

    Live finance-specific insights

    View All

    Liquidia Corporation Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    Recorded $51.7 million in net product sales of YUTREPIA™ as launch momentum continuesAchieved profitability in the first full quarter of YUTREPIA salesMore than 2,000 unique patient prescriptions and 1,500 patient starts to dateCompany to host webcast today at 8:30 a.m. ET MORRISVILLE, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced its financial results for the third quarter ended September 30, 2025. The company will also host a webcast at 8:30 a.m. Eastern Time on November 3, 2025, to review financ

    11/3/25 6:30:00 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Liquidia Corporation to Report Third Quarter 2025 Financial Results on November 3, 2025

    MORRISVILLE, N.C., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its third quarter 2025 financial results on Monday, November 3, 2025. The company will host a webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update. The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location. About Liquidia CorporationLiquidia Corporation is a b

    10/27/25 8:30:00 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    YUTREPIA™ surpasses 900 unique patient prescriptions and 550 patient starts within 11 weeks after approval to treat PAH and PH-ILDPositive interim data from ASCENT trial reinforces YUTREPIA's tolerability and efficacy profile in PH-ILD with median improvement in six-minute walk distance of 31.5 meters at Week 16Company to host webcast today at 8:30 a.m. ET MORRISVILLE, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, today announced its financial results for the second quarter ended June 30, 2025. The company will also host a webcast at 8:30 a.m. Eastern

    8/12/25 6:30:45 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGRX
    $ALZN
    $ANIX
    $BLI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Regulus Therapeutics Inc.

    SC 13G/A - Regulus Therapeutics Inc. (0001505512) (Subject)

    11/14/24 5:46:12 PM ET
    $RGLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Trevena Inc.

    SC 13G/A - TREVENA INC (0001429560) (Subject)

    11/14/24 4:43:11 PM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Regulus Therapeutics Inc.

    SC 13G/A - Regulus Therapeutics Inc. (0001505512) (Subject)

    11/14/24 4:32:07 PM ET
    $RGLS
    Biotechnology: Pharmaceutical Preparations
    Health Care